Myriad Genetics - Upgrades & Downgrades
NEW YORK (TheStreet) -TheStreet Ratings' stock model downgraded Myriad Genetics Inc (MYGN) to 'Hold' from 'Buy'. Net income at this $1.8 billion market cap, health diagnostics company shrank by 31.6% to $24.2 million in the fiscal second quarter compared to the year earlier quarter.
TheStreet Ratings released rating changes on seven U.S. common stocks for January 28, 2011. In total, three stocks were upgraded and four stocks were downgraded by our stock model.
In the fiscal second quarter, Myriad Genetics reported $100.4 million in revenue, an increase of 8.3% compared to the year earlier quarter. Learn more about Myriad Genetics: Company Profile, Income Statement, Balance Sheet, Stock Ratios, Analyst Ratings.
$658 million market cap, pharmaceutical company, Simcere Pharmaceutical Group ADR (SCR) was upgraded to 'Buy' from 'Hold'. In third quarter results, Simcere Pharmaceutical Group turned in a profit of $8.3 million, an increase of 243.6% when compared to the year earlier quarter. Over the same time period, revenue grew by 29.4% to $80.2 million. Learn more about Simcere Pharmaceutical Group: Company Profile, Income Statement, Balance Sheet, Stock Ratios, Analyst Ratings.
-- Reported by Kevin Baker in Jupiter, FL.For additional Investment Research check out our Ratings Research Center.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
